bioAffinity Technologies adds two new board members

bioAffinity Technologies Inc. (NASDAQ: BIAF, BIAFW) appointed Roberto Rios and John J. Oppenheimer to its board of directors, the biotechnology company announced.

Rios brings over 40 years of executive leadership in corporate finance and governance across biotechnology, medical devices, and construction industries. He previously held financial leadership positions at ILEX Oncology, BioMedical Enterprises, and Bartlett Cocke General Contractors. He currently serves on the boards of CCC Group and Stem Cell Reserve.

Oppenheimer serves as Director of Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey-Rutgers. He has participated in more than 180 clinical studies and authored over 260 publications. Oppenheimer has held leadership positions with the American Board of Allergy and Immunology, the American Academy of Allergy, Asthma & Immunology, and the American College of Allergy, Asthma & Immunology.

"Mr. Rios' business and financial expertise combined with Dr. Oppenheimer's clinical leadership will be invaluable as we increase sales of CyPath Lung, develop companion diagnostics for asthma and COPD, and strengthen our financial position," said Maria Zannes, President and CEO of bioAffinity Technologies.

The company also announced that Gary Rubin stepped down from the board for personal reasons, not due to disagreement with the company or its operations. Zannes said the company was grateful for Rubin's contributions over the past seven years.

bioAffinity Technologies develops noninvasive diagnostics for early detection of lung cancer and other diseases. The company's CyPath Lung test uses flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy.

You May Also Be Interested In